<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">ORAL02.02 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis Topic: Medical Oncology</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">James</forename><surname>Yao</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">University of Texas MD Anderson Cancer Center</orgName>
								<address>
									<settlement>Houston</settlement>
									<region>TX</region>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">United States of America</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nicola</forename><surname>Fazio</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution" key="instit1">Istituto Europeo di Oncologia</orgName>
								<orgName type="institution" key="instit2">IRCCS</orgName>
								<address>
									<region>Milano</region>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roberto</forename><surname>Buzzoni</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Fondazione IRCCS</orgName>
								<orgName type="institution">Istituto Nazionale dei Tumori</orgName>
								<address>
									<settlement>Milano</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gianfranco</forename><forename type="middle">Delle</forename><surname>Fave</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">Azienda Ospedaliera Sant&apos;Andrea</orgName>
								<orgName type="institution" key="instit2">Università La Sapienza</orgName>
								<address>
									<addrLine>5 Netherlands Cancer Institute</addrLine>
									<settlement>Rome</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Antoni van Leeuwenhoek</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Margot</forename><surname>Tesselaar</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Edward</forename><surname>Wolin</surname></persName>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Cedars-Sinai Medical Center</orgName>
								<orgName type="department" key="dep2">States of America</orgName>
								<address>
									<settlement>Los Angeles</settlement>
									<region>CA</region>
									<country>United</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><forename type="middle">Van</forename><surname>Cutsem</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">University Hospitals Gasthuisberg/Leuven and K U Leuven</orgName>
								<address>
									<addrLine>8 S. Orsola-Malpighi Hospital</addrLine>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">States of America</orgName>
								<orgName type="institution">University of Bologna</orgName>
								<address>
									<addrLine>9 Moffitt Cancer Center, 10</addrLine>
									<settlement>Bologna, Tampa, Tampa</settlement>
									<region>FL</region>
									<country>Italy, United</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paola</forename><surname>Tomassetti</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jonathan</forename><surname>Strosberg</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Maurizio</forename><surname>Voi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lida</forename><surname>Pacaud</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Antonia</forename><surname>Ridolfi</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Simron</forename><surname>Singh</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marianne</forename><surname>Pavel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Matthew</forename><surname>Kulke</surname></persName>
						</author>
						<title level="a" type="main">ORAL02.02 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis Topic: Medical Oncology</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">D2D68F4ECFCF3FAAE5C2D778849CC4E7</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:28+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Conclusion: With manageable toxicity, Rova-T demonstrated encouraging single agent anti-tumor activity and durability in recurrent or refractory SCLC.</s><s>A single-arm pivotal study in third-line DLL3-expressing SCLC is currently enrolling (NCT02674568).</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Novartis Pharmaceuticals Corporation, New Jersey, NJ/ United States of America, 11 Novartis Pharma AG, Basel/ Switzerland, 12 Novartis Pharma S.A.S, Rueil-Malmaison/ France, <ref type="bibr">13</ref> Sunnybrook Health Sciences Centre, Toronto, ON/Canada, 14 Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin/Germany, 15 Dana Farber Cancer Institute, Boston, MA/United States of America Background: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67;</s><s>P&lt;0.00001.</s><s>This subgroup analysis evaluated efficacy and safety of EVE in pts with lung NET from RADIANT-4.</s><s>Methods: In RADIANT-4 study, pts were randomized (2:1) to EVE 10 mg/d or PBO, both with best supportive care.</s><s>The present analysis reports subgroup of lung NET.</s><s>Results: Of 302 pts, 90 had lung NET (EVE, n¼63 and PBO, n¼27).</s><s>Median age, 65 years; males: 52%; most pts (99%) had well-differentiated disease; WHO PS 0/1/2: 71%/28%/1%; Caucasian: 86%.</s><s>Prior therapies (EVE vs PBO) included: somatostatin analogues (mostly for tumor growth control; 43% vs 41%), surgery (52% vs 67%), and chemotherapy (40% vs 48%).</s><s>Median PFS (95% CI) by central review (EVE vs PBO) was 9.2 (6.8-10.9)</s><s>vs 3.6 (1.9-5.1)</s><s>months with tumor progression risk-reduction by 50% in EVE (HR, 0.50; 95% CI, 0.28-0.88).</s><s>Most frequent (5%) G3/4 adverse events irrespective of drug-relationship (EVE vs PBO) were stomatitis (11% vs 0), hyperglycemia (10% vs 0), diarrhea (7% vs 0), hypophosphatemia (7% vs 0), dyspnea (5% vs 7%), and hypertension (0 vs 7%).</s><s>Conclusion: EVE treatment improved PFS by 6 months and reduced tumor progression risk by 50% in pts with advanced, progressive, nonfunctional lung NET compared to PBO.</s><s>EVE safety profile was similar to overall RADIANT-4 population.</s><s>Methods: Patients who were treated with RTCT for LANSCLC and underwent 18 F-FDG PET/CT 7-10 days post-therapy were retrospectively analyzed.</s><s>Tumor metabolic response was measured using a 5 visual score scale with level 0-2 being FDG uptake lower than or comparable to noncardiac mediastinal structures (NCMS).</s><s>Thus, patients who achieved level 0-2 score were considered complete metabolic responders (CMR) while those with level 3-4, having uptake greater than NCMS was considered incomplete metabolic responders (IMR).</s><s>We offered boost RT for patients with IMR.</s><s>We also measured the maximum standard uptake value (SUVmax) retrospectively and correlated with visual score scale and clinical outcome.</s><s>RTCT comprised a median total dose of 63 Gy/35 fractions (F) and 2-4 cycles of cisplatin based chemotherapy.</s><s>Boost dose RT November 2016 Abstracts S253</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ORAL02.03 Robust Correlation Between Metabolic Response Measured with 18 F-FDG PET Soon After Therapy and Clinical Outcome in Lung Cancer</head></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Topic: Radiation Oncology Noah C. Choi, Justin Gainor, Jeanne Ackman, Ruth Lim, Gregory C. Sharp, Georges El Fakhri, Andrzej Niemierko Massachusetts General Hospital/ Harvard Medical School, Boston, MA/United States of America Background: To investigate whether tumor metabolic response measured with 18 F-FDG PET immediately after concurrent radiotherapy-chemotherapy (RTCT) is correlated with clinical outcome in patients with locally advanced nonesmall cell lung cancer (LANSCLC).</s></p></div></figDesc></figure>
		</body>
		<back>
			<div type="references">

				<listBibl/>
			</div>
		</back>
	</text>
</TEI>
